• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Curis

Curis

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. Estrogen Receptor Positive (ER+) Breast Cancer Treatment Landscape & Competitive Analysis Report 2017 - Research and Markets

    Estrogen Receptor Positive (ER+) Breast Cancer Treatment Landscape & Competitive Analysis Report 2017 - Research and Markets

  2. An ETF for This Lagging Sector

    Biotech companies' returns have diverged from the broader market in recent weeks amid concerns over greater regulation and price discounting.

1

©2017 Morningstar Advisor. All right reserved.